Pharmaceutical products | Tenderlake

Pharmaceutical products

Contract Value:
-
Notice Type:
Contract award notice
Published Date:
25 November 2021
Closing Date:
Location(s):
UKE YORKSHIRE AND THE HUMBER (UK UNITED KINGDOM)
Description:
NHS Framework Agreement for the Supply of Direct Oral Anticoagulant (DOAC) Medicines for the NHS in England

NHS Framework Agreement for the supply of Direct Oral Anticoagulants (DOACs) for the NHS in England. Also known as Novel Oral Anticoagulants (NOACs).Period of Framework: 01/01/2022 - 31/04/2024 with an option to extend (at the Authority’s discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 39 months)

NHS Framework Agreement for the supply of Direct Oral Anticoagulants (DOACs) for the NHS in England. Also known as Novel Oral Anticoagulants (NOACs).Period of Framework: 01/01/2022 - 31/04/2024 with an option to extend (at the Authority’s discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 39 months)

Awarded to:
Bayer Ltd, Reading (UK)
Bayer Ltd, Reading (UK)
Bayer Ltd, Reading (UK)
Bristol Myers Squibb, Uxbridge (UK)
Bristol Myers Squibb, Uxbridge (UK)
Bristol Myers Squibb, Uxbridge (UK)
Daiichi Sankyo UK Ltd, Uxbridge (UK)
Daiichi Sankyo UK Ltd, Uxbridge (UK)
Daiichi Sankyo UK Ltd, Uxbridge (UK)
Download full details as .pdf
The Buyer:
The NHS Commissioning Board (operating under the name of NHS England)
CPV Code(s):
33600000 - Pharmaceutical products
33690000 - Various medicinal products